Familial breast cancer: characteristics and outcome of BRCA 1- positive and negative cases

详细信息    查看全文

• 作者：Andrea Veronesi (1)
  Clelia de Giacomi (1)
  Maria D Magri (1)
  Davide Lombardi (1)
  Martina Zanetti (1)
  Cristina Scuderi (1)
  Riccardo Dolcetti (2)
  Alessandra Viel (2)
  Diana Crivellari (1)
  Ettore Bidoli (3)
  Mauro Boiocchi (2)
  
• 刊名：BMC Cancer
• 出版年：2005
• 出版时间：December 2005
• 年：2005
• 卷：5
• 期：1
• 全文大小：588KB
• 参考文献：1. Blackwood MA, Weber BL: BRCA1 and BRCA2: from molecular genetics to clinical medicine. / J Clin Oncol 1998, 16: 1969-977.
  2. Chappuis PO, Nethercot V, Foulkes WD: Clinico-pathological characteristics of BRCA-1 and BRCA-2 related breast cancer. / Semin Surg Oncol 2000, 18: 287-95. CrossRef
  3. Albano W, Recabaren J, Lynch H: Natural history of hereditary cancer of the breast and colon. / Cancer 1982, 50: 360-63. CrossRef
  4. Andersson D, Badzioch M: Survival in familial breast cancer patients. / Cancer 1986, 58: 360-65. CrossRef
  5. Chang J, Elledge RM: Clinical management of women with genomic BRCA1 and BRCA2 mutations. / Breast Cancer Res Treat 2001, 69: 101-13. CrossRef
  6. Foulkes WD, Metcalfe K, Hanna W, Lynch HT, Ghadirian P, Tung N, Olopade O, Weber B, McLennan J, Olivotto IA, Sun P, Chappuis PO, Bégin LR, Brunet J-S, Narod SA: Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA-1 related breast carcinoma. / Cancer 2003, 98: 1569-577. CrossRef
  7. Foulkes WD, Chappuis PO, Wong N, Brunet JS, Vesprini D, Rozen F: Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. / Ann Oncol 2000, 11: 307-13. CrossRef
  8. Ansquer Y, Gautier C, Fourquet A, Asselain B, Stoppa-Lyonnet D: Survival in early-onset BRCA1 breast cancer patients: Institute Curie Breast Cancer Group. / Lancet 1998, 352: 541. CrossRef
  9. Haffty BG, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC, Glazer PM, Ward B, Carter D, Matloff E, Bale AE, Alvarez-Franco M: Outcome of conservatively managed early-onset breast cancer by BRCA 1/2 status. / Lancet 2002, 359: 1471-477. CrossRef
  10. Johannsson OT, Ranstam J, Borg A, Olsson H: Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. / J Clin Oncol 1998, 16: 397-04.
  11. Verhhoog LG, Brekelmans CTM, Seynaeve C, Dahmen G, van Geel AN, Bartels CC, Tilanus-Linthorst MM, Wagner A, Devilee P, Halley DJ, van den Ouweland AM, Meijers-Heijboer EJ, Klijn JG: Survival in hereditary breast cancer associated with germline mutations of BRCA2. / J Clin Oncol 1999, 17: 3396-402.
  12. Eerola H, Vahteristo P, Sarantaus L, Kyyronen P, Pirhonen S, Blomqvist C, Pukkala E, Nevanlinna H, Sankila R: Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland. / Int J Cancer 2001, 93: 368-72. CrossRef
  13. Nicoletto MO, Donach M, De Nicolo A, Artioli G, Banna G, Monfardini S: BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling. / Cancer Treatment Reviews 2001, 27: 295-04. CrossRef
  14. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/5/70/prepub
  
• 作者单位：Andrea Veronesi (1)
  Clelia de Giacomi (1)
  Maria D Magri (1)
  Davide Lombardi (1)
  Martina Zanetti (1)
  Cristina Scuderi (1)
  Riccardo Dolcetti (2)
  Alessandra Viel (2)
  Diana Crivellari (1)
  Ettore Bidoli (3)
  Mauro Boiocchi (2)
  
  1. Division of Medical Oncology C, Centro di Riferimento Oncologico, Aviano, Italy
  2. Division of Experimental Oncology I, Centro di Riferimento Oncologico, Aviano, Italy
  3. Epidemiology Unit Centro di Riferimento Oncologico, Aviano, Italy
  
• ISSN：1471-2407

文摘

Background The clinical and pathological characteristics and the clinical course of patients with breast cancer and BRCA 1- mutation are poorly known. Methods From 1997, patients with breast cancer and a family history of breast or ovarian cancer were offered BRCA testing. The clinical and pathological features of patients with known BRCA status were retrospectively assessed and comparisons were made between cancers arising in BRCA positive and BRCA wild type (WT) patients respectively. Type of treatment, pattern of relapse, event (local relapse, contralateral breast cancer, metastases) free and overall survival were also compared in the two groups. Out of the 210 patients tested, 125 had been treated and followed-up at our Institution and were evaluated in this study. Results BRCA positive patients tended to be more often premenopausal (79% vs 65%) and to have positive lymphnodes (63% vs 49%), poorly differentiated tumours (76% vs 40% -p = 0.002 at univariate analysis, not significant at multivariate analysis) and negative estrogen receptors (43% vs 29%). Treatment was not different in the two groups. In the 86 BRCA-WT patients, the first event was a local relapse in 3 (3%), metachronous contralateral breast cancer in 7 (8%) and distant metastases in 16 (19%). In the 39 BRCA positive patients, the corresponding figures were 3 (8%), 8 (21%) and 3 (8%). There was no difference in event free survival, with a median of 180 months in both groups of patients. At 20 years, projected survival was 85% for BRCA positive patients and 55% for BRCA-WT, but this difference was not statistically significant. Conclusion Although BRCA positive patients have more frequently negative prognostic factors, their prognosis appears to be equal to or better than in patients with BRCA-WT.